Western blot results showed that the levels of CyclinB1, CDC2, CDK4, CDK6, CyclinB1 and CyclinD1 of GBM cells were downregulated after Mito-LND treatment in a dose-dependent manner (Fig. 2E, F). Here, CCND1 is linked to glioblastoma.